Literature DB >> 24175252

Role of renal proximal tubule transport in thiazolidinedione-induced volume expansion.

George Seki1, Yoko Endo, Masashi Suzuki, Hideomi Yamada, Shoko Horita, Toshiro Fujita.   

Abstract

Thiazolidinediones (TZDs), pharmacological activators of peroxisome-proliferator-activated receptors γ (PPARγ), significantly improve insulin resistance and lower plasma glucose concentrations. However, the use of TZDs is associated with plasma volume expansion, the mechanism of which has been a matter of controversy. Originally, PPARγ-mediated enhanced transcription of the epithelial Na channel (ENaC) γ subunit was thought to play a central role in TZD-induced volume expansion. However, later studies suggested that the activation of ENaC alone could not explain TZD-induced volume expansion. We have recently shown that TZDs rapidly stimulate sodium-coupled bicarbonate absorption from renal proximal tubule (PT) in vitro and in vivo. TZD-induced transport stimulation was dependent on PPARγ/Src/EGFR/ERK, and observed in rat, rabbit and human. However, this stimulation was not observed in mouse PTs where Src/EGFR is constitutively activated. Analysis in mouse embryonic fibroblast cells confirmed the existence of PPARγ/Src-dependent non-genomic signaling, which requires the ligand binding ability but not the transcriptional activity of PPARγ. The TZD-induced enhancement of association between PPARγ and Src supports an obligatory role for Src in this signaling. These results support the view that TZD-induced volume expansion is multifactorial. In addition to the PPARγ-dependent enhanced expression of the sodium transport system(s) in distal nephrons, the PPARγ-dependent non-genomic stimulation of renal proximal transport may be also involved in TZD-induced volume expansion.

Entities:  

Keywords:  Edema; Epithelial Na channel; NBCe1; NHE3; Peroxisome-proliferator-activated receptors γ; Thiazolidinediones; Volume expansion

Year:  2012        PMID: 24175252      PMCID: PMC3782215          DOI: 10.5527/wjn.v1.i5.146

Source DB:  PubMed          Journal:  World J Nephrol        ISSN: 2220-6124


  37 in total

1.  Pulmonary edema associated with troglitazone therapy.

Authors:  I B Hirsch; J Kelly; S Cooper
Journal:  Arch Intern Med       Date:  1999 Aug 9-23

Review 2.  Signaling pathways in insulin action: molecular targets of insulin resistance.

Authors:  J E Pessin; A R Saltiel
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

3.  Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney.

Authors:  Emily Borsting; Vicki Pei-Chun Cheng; Chris K Glass; Volker Vallon; Robyn Cunard
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-14

4.  Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.

Authors:  Hui Zhang; Aihua Zhang; Donald E Kohan; Raoul D Nelson; Frank J Gonzalez; Tianxin Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-14       Impact factor: 11.205

5.  Effect of various diuretic treatments on rosiglitazone-induced fluid retention.

Authors:  Janaka Karalliedde; Robin Buckingham; Margaret Starkie; Daniel Lorand; Murray Stewart; Giancarlo Viberti
Journal:  J Am Soc Nephrol       Date:  2006-11-08       Impact factor: 10.121

6.  Insulin stimulates volume absorption in the rabbit proximal convoluted tubule.

Authors:  M Baum
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

7.  Roles of ERK and cPLA2 in the angiotensin II-mediated biphasic regulation of Na+-HCO3(-) transport.

Authors:  Yuehong Li; Hideomi Yamada; Yoshihiro Kita; Motoei Kunimi; Shoko Horita; Masashi Suzuki; Yoko Endo; Takao Shimizu; George Seki; Toshiro Fujita
Journal:  J Am Soc Nephrol       Date:  2007-12-19       Impact factor: 10.121

8.  PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice.

Authors:  Michael J Ryan; Sean P Didion; Satya Mathur; Frank M Faraci; Curt D Sigmund
Journal:  Hypertension       Date:  2004-01-26       Impact factor: 10.190

9.  Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects.

Authors:  L J Goodyear; F Giorgino; L A Sherman; J Carey; R J Smith; G L Dohm
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

Review 10.  Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.

Authors:  Sunder Mudaliar; Anna R Chang; Robert R Henry
Journal:  Endocr Pract       Date:  2003 Sep-Oct       Impact factor: 3.443

View more
  5 in total

1.  Alteration of NCoR corepressor splicing in mice causes increased body weight and hepatosteatosis without glucose intolerance.

Authors:  Michael L Goodson; Briana M Young; Chelsea A Snyder; Amy C Schroeder; Martin L Privalsky
Journal:  Mol Cell Biol       Date:  2014-09-02       Impact factor: 4.272

Review 2.  The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.

Authors:  Rabea Asleh; Mohammad Sheikh-Ahmad; Alexandros Briasoulis; Sudhir S Kushwaha
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

Review 3.  Effect of glucose-lowering therapies on heart failure.

Authors:  Michael Nassif; Mikhail Kosiborod
Journal:  Nat Rev Cardiol       Date:  2018-01-25       Impact factor: 32.419

Review 4.  Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug.

Authors:  Lorenzo Nesti; Domenico Tricò; Alessandro Mengozzi; Andrea Natali
Journal:  Cardiovasc Diabetol       Date:  2021-05-18       Impact factor: 9.951

5.  Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study.

Authors:  Jeong Mi Kim; Sang Soo Kim; Jong Ho Kim; Mi Kyung Kim; Tae Nyun Kim; Soon Hee Lee; Chang Won Lee; Ja Young Park; Eun Sook Kim; Kwang Jae Lee; Young Sik Choi; Duk Kyu Kim; In Joo Kim
Journal:  Diabetes Metab J       Date:  2019-07-11       Impact factor: 5.376

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.